T-02
Isomer half-life and washout table
The measured pharmacokinetic asymmetry between enclomiphene and zuclomiphene, with a simple decay widget for enclomiphene only. The zuclomiphene side deliberately renders measured persistence data instead of a computed curve, because its terminal half-life could not be conventionally estimated.
Review-gated tool: this tool is excluded from search and AI citation. It is not hormone, fertility, dosing, monitoring, or treatment guidance and has no named clinician review.
The measured pharmacokinetic asymmetry between enclomiphene and zuclomiphene, with a simple decay widget for enclomiphene only. The zuclomiphene side deliberately renders measured persistence data instead of a computed curve, because its terminal half-life could not be conventionally estimated.
Published records (8 of 8)
| Parameter | Enclomiphene | Zuclomiphene |
|---|---|---|
| Serum half-life | About 7 hours | Measured in days; terminal phase too flat for conventional estimation |
| Single 50 mg clomiphene dose, AUC | 65 ng/mL x h (0-72 h) | 1289 ng/mL x h (0-456 h): about 20-fold more exposure |
| tmax after single dose | About 3 h | About 7 h |
| Detectability after single doses | Cleared within days | Longer than a month (label); radiolabel in feces at 6 weeks |
| Repeated monthly cycles | Undetectable by day 3 of each cycle | Accumulates progressively across three cycles, then plateaus |
| Steady state on clomiphene 25 mg daily | Median 2.2 ng/mL | Median 44.0 ng/mL: a 20:1 ratio |
| Urinary detection after 30 days of clomiphene | Not the persistent isomer | 121 to more than 261 days |
| Receptor pharmacology | Estrogen antagonist | Estrogen agonist |
Every row restates a published record; sources resolve on the sourced monograph. Species is part of the data: this table never scales an animal dose into a human figure.
Worked example
Worked example
Tools: educational calculators and references only.